Cordyceps militaris and ganoderma lucidum spore powder composite preparation and application thereof
Through the microcapsule embedding technology, the carboxylic acid group ratio of the microcapsule wall material was adjusted, and the problem of insufficient absorption of Cordyceps sinensis and Ganoderma lucidum spore powder in the composite preparation was solved, and the two were absorbed and synergistically affected in the small intestine. Enhanced anti-aging and anti-aging effects.
Patent Information
- Application Number
- CN202411523554.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-30
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-10-30
AI Technical Summary
Among the existing composite preparations, the absorption mechanism and absorption methods of Cordyceps sinensis and Ganoderma lucidum spore powder are different, and it is difficult to achieve the purpose of fully absorbing and exerting the function of various components.
Microcapsule embedded particles are adopted, the outer layer is a polylactic acid-glycolic acid copolymer film, the inner layer is a composite particle coated with Cordyceps extract and microcapsule coated with Ganoderma lucidum spore powder. By adjusting the microcapsule wall material The ratio of carboxylic acid groups to protect Cordyceps extract from gastric juice, and the Ganoderma lucidum spore powder is pre-treated in the gastric juice, so that both reach the small intestine at the same time and are fully absorbed.
The simultaneous absorption of Cordyceps sinensis and Ganoderma lucidum spore powder is achieved, which enhances the anti-aging and anti-aging effect, and ensures the synergistic effect and bioavailability of the ingredients.
Smart Images

Figure CN119033092A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of composite preparations, and in particular relates to a cordyceps militaris and ganoderma lucidum spore powder composite preparation and application thereof. Background Art
[0002] The common health products on the market today usually contain a single ingredient, while compound preparations can provide richer nutrition and health benefits through the synergistic effect of multiple ingredients. Cordyceps militaris and Ganoderma lucidum spore powder are both precious Chinese medicinal materials with effects such as enhancing immunity and anti-oxidation.
[0003] However, since the absorption mechanism and absorption method of each component in the compound preparation are different, it is difficult to achieve the goal of fully absorbing multiple components and exerting their effects. Summary of the invention
[0004] The invention aims to provide a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation and application thereof, and adjusts the sustained-release time and sustained-release site of the components according to the absorption characteristics of the various components by the human body, so that each component can be fully absorbed and the synergistic effect between the components is improved.
[0005] The above technical objectives of the present invention are achieved through the following technical solutions: The present invention provides a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation, wherein the composite preparation is microcapsule-embedded particles, the outer layer is a polylactic acid-glycolic acid copolymer film, and the inner layer is a composite particle of microcapsule-coated Cordyceps militaris extract and microcapsule-coated Ganoderma lucidum spore powder; Calculated by weight, the composite particles include the following components: 20-30 parts of microcapsule-coated Cordyceps militaris extract, 30-50 parts of microcapsule-coated Ganoderma lucidum spore powder and 10-15 parts of adjuvant; The microcapsule encapsulates the Cordyceps militaris extract, and includes, from the outside to the inside: an enteric layer and the Cordyceps militaris extract; The microcapsule encapsulates the ganoderma spore powder, and comprises from the outside to the inside: a polymer sustained-release coating and the ganoderma spore powder.
[0006] Furthermore, the materials of the polymer sustained-release coating and the enteric layer are both polyacrylic acid resin; The ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer is 1:(2-10).
[0007] Furthermore, the material of the enteric layer includes a polyacrylic acid resin with a high carboxylic acid group density and a polyacrylic acid resin with a low carboxylic acid group density.
[0008] Furthermore, the mass ratio of the low carboxylic acid group density polyacrylic acid resin to the high carboxylic acid group density polyacrylic acid resin is calculated according to the following formula: ; in, is the mass ratio of the low carboxylic acid group density polyacrylic acid resin to the high carboxylic acid group density polyacrylic acid resin, and the unit is 1; It is the ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer, and the unit is 1; is the thickness of the polymer sustained-release coating, in nm; is the thickness of the enteric layer, in nm.
[0009] Furthermore, the particle size of the composite particles is 20-80 μm.
[0010] Furthermore, the particle size of the composite particles is 1-5 μm.
[0011] Furthermore, the particle size of the microcapsule-encapsulated Cordyceps militaris extract is 0.1-0.8 μm; and the particle size of the microcapsule-encapsulated Ganoderma lucidum spore powder is 0.1-0.5 μm.
[0012] Furthermore, the preparation method of the microcapsule-coated Cordyceps militaris extract is as follows: Dissolving polyacrylic acid resin in a solvent and stirring evenly to form a homogeneous polyacrylic acid resin solution; Add the Cordyceps militaris extract to the polyacrylic acid resin solution and stir evenly; Add an appropriate amount of emulsifier to form an emulsion; The emulsion is emulsified under high-speed stirring to form stable emulsion particles; Adding a cross-linking agent dropwise into the emulsion to form cross-links between polyacrylic acid resin molecules, thereby forming the wall material of the microcapsule; Continue stirring the emulsion to allow the cross-linking reaction to proceed fully until stable microcapsules are formed; Centrifugation and filtration to separate the microcapsules from the reaction mixture; The microcapsules are washed to remove unreacted polyacrylic acid resin and other impurities, and then dried to obtain the microcapsule-coated Cordyceps militaris extract.
[0013] Furthermore, the preparation method of the composite preparation provided by the present invention is as follows: Mixing the microcapsule-encapsulated Cordyceps militaris extract and the microcapsule-encapsulated Ganoderma lucidum spore powder in proportion; Add auxiliary agents and mix well; The uniformly mixed materials are granulated by a granulator to form composite particles; dissolving PLGA in a solvent to form a PLGA solution; The composite particles are immersed in a PLGA solution so that the surface of the composite particles is evenly coated with a layer of PLGA film; and drying to form the composite preparation.
[0014] The invention provides an application of a cordyceps militaris and ganoderma lucidum spore powder composite preparation, wherein the composite preparation is dissolved in water to prepare an instant drinkable granule.
[0015] In some preferred embodiments, the composite preparation is made into capsules (soft capsules or hard capsules), tablets, granules, granules, pills, powders, pastes, and pills.
[0016] In summary, the present invention has the following beneficial effects: The invention provides a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation and application thereof. By adjusting the ratio of carboxylic acid groups in the microcapsule wall material, the Cordyceps militaris extract can be protected from being eroded by gastric juice and the Ganoderma lucidum spore powder can be pre-treated by gastric juice, so that the two can reach the small intestine at the same time and be fully absorbed, thereby having an anti-aging effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 It is a schematic diagram of the structure of the composite preparation of the present invention; Figure 2 This is a schematic diagram of the structure of the microcapsule-coated Cordyceps militaris extract of the present invention; Figure 3 The schematic diagram is a structural diagram of the microcapsule-encapsulated Ganoderma lucidum spore powder of the present invention.
[0018] Figure numerals: 1. polylactic acid-glycolic acid copolymer film; 2. composite particles; 3. microcapsule-coated Cordyceps militaris extract; 4. microcapsule-coated Ganoderma lucidum spore powder; 31. enteric layer; 32. Cordyceps militaris extract; 41. polymer sustained-release coating; 42. Ganoderma lucidum spore powder. DETAILED DESCRIPTION
[0019] In order to further explain the technical means and effects adopted by the present invention to achieve the predetermined purpose of the invention, a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation and its application proposed by the present invention, its specific implementation method, characteristics and effects are described in detail as follows.
[0020] Cordyceps militaris extract is an herb that has been used in traditional Chinese medicine for hundreds of years. It is extracted from a fungus that parasitizes insect pupae and is often used to support the immune system, increase energy and improve physical health. Cordyceps militaris extract contains a variety of bioactive ingredients, including polysaccharides, steroids and adenosine, which have antioxidant, anti-inflammatory and endurance-enhancing effects. Among them, adenosine is an important ingredient in Cordyceps militaris, which helps improve energy metabolism, supports cardiovascular health, and has certain anti-fatigue and antioxidant effects.
[0021] However, some components in Cordyceps militaris extract, especially the more sensitive active ingredients such as adenosine and some polysaccharides, will be partially destroyed by gastric acid. The acidic environment of gastric acid and the action of digestive enzymes may cause the degradation of these components, thus affecting their biological activity.
[0022] In addition, Ganoderma lucidum spore powder is a powder extracted from the mature spores of Ganoderma lucidum, a medicinal fungus widely used in traditional Chinese medicine and complementary medicine. Ganoderma lucidum spore powder is considered to be the essence of Ganoderma lucidum and is rich in a variety of biologically active ingredients, including: triterpenoids, polysaccharides, adenosine, etc. Among them, triterpenoids help to enhance the immune system and enhance the body's immune response.
[0023] However, due to the hardness of the spore shell in Ganoderma lucidum spore powder, the actual absorption effect will be affected. Therefore, Ganoderma lucidum spore powder needs to stay in the gastric juice for a period of time. After being processed by gastric acid, when the effective ingredients in Ganoderma lucidum spore powder reaches the small intestine of the human body, they can be fully absorbed. If Ganoderma lucidum spore powder stays in the gastric juice for too long, gastric acid will also destroy the biological activity of adenosine and triterpenoid compounds in Ganoderma lucidum spore powder, affecting the absorption effect.
[0024] Therefore, how to simultaneously protect the adenosine in the Cordyceps militaris extract and the Ganoderma lucidum spore powder from being eroded by gastric acid and enable the Ganoderma lucidum spore powder to be properly treated by gastric juice is a difficult problem in preparing a composite preparation of Ganoderma lucidum spore powder and Cordyceps militaris extract.
[0025] In view of the above problems, the Cordyceps militaris and Ganoderma lucidum spore powder composite preparation provided in this specific embodiment can not only protect the Cordyceps militaris extract from being eroded by gastric juice, but also enable the Ganoderma lucidum spore powder to be pre-treated by gastric juice, so that both can reach the small intestine at the same time and be fully absorbed.
[0026] The composite preparation provided in this specific embodiment is a microcapsule-embedded particle, the outer layer of which is a polylactic acid-glycolic acid copolymer film, and the inner layer is a composite particle of microcapsule-coated Cordyceps militaris extract and microcapsule-coated Ganoderma lucidum spore powder; The composite particles include the following components, calculated by weight: 20-30 parts of microcapsule-coated Cordyceps militaris extract, 30-50 parts of microcapsule-coated Ganoderma lucidum spore powder and 10-15 parts of adjuvant; The microcapsule encapsulates the Cordyceps militaris extract, and includes, from the outside to the inside: an enteric layer and the Cordyceps militaris extract; The microcapsule encapsulates the ganoderma spore powder, and comprises from the outside to the inside: a polymer sustained-release coating and the ganoderma spore powder.
[0027] As can be seen from the above, different microcapsules are used for different components. According to the pH value of gastric acid, the wall material of the microcapsule coated with Cordyceps militaris extract is made of a more acid-resistant material so that it can reach the small intestine smoothly, while the wall material of the microcapsule coated with Ganoderma lucidum spore powder is made of a material that can be sustained-released in gastric acid, so that it is gradually released and reaches the small intestine together with Cordyceps militaris after being treated with gastric acid and is absorbed at the same time.
[0028] In one example, the materials of the polymer sustained-release coating and the enteric layer are both polyacrylic acid resin; the ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer is 1:(2~10).
[0029] It is understandable that the degree of cross-linking affects the dissolution rate and acid resistance of the polymer. Low to moderate cross-linking allows the encapsulated material to dissolve moderately in an acidic environment, thereby controlling the release rate. Too high a cross-linking degree may result in too slow dissolution, while too low a cross-linking degree may result in insufficient protection. In polymer science, the degree of cross-linking usually refers to the cross-linking density between polymer chains, that is, the degree to which polymer molecules are connected by chemical bonds. The value of the cross-linking degree is usually expressed as the cross-linking density or the proportion of the cross-linking agent. The specific range of values depends on the materials used and the application scenario. In drug preparations, especially in microencapsulation technology, the degree of cross-linking usually needs to be controlled in a more moderate range to achieve optimal drug release characteristics.
[0030] In this specific embodiment, the crosslinking density is used to represent the crosslinking degree of the polymer, and the sustained release rate of the Ganoderma lucidum spore powder and the Cordyceps militaris extract in gastric acid is determined according to the ratio of the crosslinking degrees, ensuring that the Cordyceps militaris extract is not eroded by gastric acid, while the Ganoderma lucidum spore powder is treated by gastric acid through sustained release.
[0031] In one example, the material of the enteric layer includes a high carboxylic acid group density polyacrylic acid resin and a low carboxylic acid group density polyacrylic acid resin.
[0032] It should be noted that the solubility and application characteristics of polyacrylic acid resins largely depend on the density of their carboxylic acid groups (-COOH). The density of carboxylic acid groups directly affects the dissolution behavior of the resin in different pH environments. Therefore, different types of polyacrylic acid resins can be distinguished by the difference in carboxylic acid group density.
[0033] It is understood that the carboxylic acid group density refers to the number of carboxylic acid groups contained per unit mass or volume in the polymer. Resins with high density are more easily dissociated and dissolved in a low pH environment, while resins with low density require a higher pH value to dissociate.
[0034] Among them, high carboxylic acid group density polyacrylic acid resin: This resin contains more methacrylic acid (MAA) or acrylic acid (AA) monomers in its structure. These monomers contain carboxylic acid groups, which allow the resin to dissolve at a lower pH value (such as below pH = 5).
[0035] Medium carboxylic acid group density polyacrylic acid resin: These resins contain a moderate amount of carboxylic acid groups and are usually soluble between pH 5 and 7.
[0036] Low carboxylic acid group density polyacrylic resin: This type of resin contains a low carboxylic acid group density and can only be dissolved at a higher pH value (such as pH=7 or above). Low carboxylic acid group density is usually achieved by introducing more neutral or hydrophobic monomers (such as methyl methacrylate, MMA).
[0037] Specifically, in this specific embodiment, in the polyacrylic acid resin with high carboxylic acid group density, the molar mass proportion of the carboxylic acid group is 30%; and the molar mass proportion of the polyacrylic acid resin with low carboxylic acid group density is 10%.
[0038] In one example, the mass ratio of the low carboxylic acid group density polyacrylic acid resin to the high carboxylic acid group density polyacrylic acid resin is calculated according to the following formula: ; in, is the mass ratio of the low carboxylic acid group density polyacrylic acid resin to the high carboxylic acid group density polyacrylic acid resin, and the unit is 1; It is the ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer, and the unit is 1; is the thickness of the polymer sustained-release coating, in nm; is the thickness of the enteric layer, in nm.
[0039] It can be understood that in the above formula, The meaning of represents the mass ratio of polyacrylic acid resin with high carboxylic acid group density relative to the resin with low carboxylic acid group density, which is used to measure the proportion of different resins in the mixture and affects the solubility and release characteristics of the final material; The meaning of indicates the relative size of the cross-linking density between the two layers (sustained-release coating and enteric layer). The cross-linking density affects the mechanical properties and dissolution behavior of the material; The meaning of represents the thickness ratio of the sustained-release coating to the enteric layer, which can affect the release rate and dissolution characteristics of the drug. Taking these factors into consideration, the formula provided in this embodiment describes the ratio of different components and structural layers in a composite material. Specifically, it relates the ratio of different types of polyacrylic acid resins. , as well as the cross-linking density ratio and thickness ratio of these resins in the respective functional layers (sustained release layer and enteric layer) in multilayer drug coatings. This relationship helps to design and optimize the release characteristics of drug formulations, such as release rate, to meet specific therapeutic needs.
[0040] Specifically, in this specific embodiment, the larger the ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer, the slower the sustained-release rate of the microcapsule-coated Cordyceps militaris extract compared to the microcapsule-coated Ganoderma lucidum spore powder. Therefore, reducing the content of low carboxylic acid group density polyacrylic acid resin in the enteric layer material can increase the sustained-release rate of the enteric layer in the small intestine, thereby ensuring that the Ganoderma lucidum spore powder and the Cordyceps militaris extract can be absorbed at the same time.
[0041] In one example, the particle size of the composite particles is 20-80 μm.
[0042] In one example, the particle size of the composite particles is 1-5 μm.
[0043] In one example, the particle size of the microcapsule-encapsulated Cordyceps militaris extract is 0.1-0.8 μm; the particle size of the microcapsule-encapsulated Ganoderma lucidum spore powder is 0.1-0.5 μm.
[0044] It can be understood that microencapsulation can prevent active ingredients from being directly exposed to an adverse environment and increase stability. Controlling the size of the microcapsules can accurately adjust the release rate of the drug. In this specific embodiment, composite particles and microcapsules of different particle sizes are provided to optimize the release characteristics of the drug, improve bioavailability and stability, and meet different dosing requirements and therapeutic effects. These settings help to achieve personalized drug treatment, maximize its therapeutic effect and minimize side effects.
[0045] In one example, the preparation method of microcapsule-encapsulated Cordyceps militaris extract is: Dissolving a polyacrylic acid resin with a high carboxylic acid group density and a polyacrylic acid resin with a low carboxylic acid group density in a solvent, and stirring the mixture to form a homogeneous polyacrylic acid resin solution; Add the Cordyceps militaris extract to the polyacrylic acid resin solution and stir evenly; Add an appropriate amount of emulsifier to form an emulsion; The emulsion is emulsified under high-speed stirring to form stable emulsion particles; Adding a cross-linking agent dropwise into the emulsion to form cross-links between polyacrylic acid resin molecules, thereby forming the wall material of the microcapsule; Continue stirring the emulsion to allow the cross-linking reaction to proceed fully until stable microcapsules are formed; Centrifugation and filtration to separate the microcapsules from the reaction mixture; The microcapsules are washed to remove unreacted polyacrylic acid resin and other impurities, and then dried to obtain the microcapsule-coated Cordyceps militaris extract.
[0046] In some preferred examples, the emulsifier is Tween 80, the cross-linking agent is glutaraldehyde, and the concentration of the cross-linking agent is determined according to the degree of cross-linking. Preferably, the concentration of the cross-linking agent is 1% to 5%wt of the polyacrylic acid resin.
[0047] In one example, the preparation method of microcapsule-coated Ganoderma lucidum spore powder is as follows: Dissolving a polyacrylic acid resin with a high carboxylic acid group density in a solvent, and stirring evenly to form a homogeneous polyacrylic acid resin solution; Add the ganoderma lucidum spore powder into the polyacrylic acid resin solution and stir evenly; Add an appropriate amount of emulsifier to form an emulsion; The emulsion is emulsified under high-speed stirring to form stable emulsion particles; Adding a cross-linking agent dropwise into the emulsion to form cross-links between polyacrylic acid resin molecules, thereby forming the wall material of the microcapsule; Continue stirring the emulsion to allow the cross-linking reaction to proceed fully until stable microcapsules are formed; Centrifugation and filtration to separate the microcapsules from the reaction mixture; The microcapsules are washed to remove unreacted polyacrylic acid resin and other impurities, and then dried to obtain the microcapsule-coated Ganoderma lucidum spore powder.
[0048] In this specific embodiment, a polyacrylic acid resin with a high density of carboxylic acid groups is used as the wall material of the Ganoderma lucidum spore powder, so that the Ganoderma lucidum spore powder can be subjected to acid treatment in gastric juice, making the spore shell more easily soluble in the intestinal juice, while not causing the Ganoderma lucidum spore powder to be overly exposed to gastric acid, resulting in the active ingredients being destroyed by gastric acid.
[0049] In some preferred examples, the emulsifier is Tween 80, the cross-linking agent is glutaraldehyde, and the concentration of the cross-linking agent is determined according to the degree of cross-linking. Preferably, the concentration of the cross-linking agent is 0.2% to 1%wt of the polyacrylic acid resin.
[0050] In one example, the preparation method of Cordyceps militaris extract adopts an alcohol extraction method to obtain more adenosine; the wall breaking rate of Ganoderma lucidum spore powder is selected to be more than 90% to improve the absorption rate of Ganoderma lucidum spore powder.
[0051] In one example, the preparation method of the compound formulation is as follows: Mixing the microcapsule-encapsulated Cordyceps militaris extract and the microcapsule-encapsulated Ganoderma lucidum spore powder in proportion; Add auxiliary agents and mix well; The uniformly mixed materials are granulated by a granulator to form composite particles; dissolving PLGA in a solvent to form a PLGA solution; The composite particles are immersed in a PLGA solution so that the surface of the composite particles is evenly coated with a layer of PLGA film; and drying to form the composite preparation.
[0052] In some preferred embodiments, the adjuvant is generally selected from β -Cyclodextrins.
[0053] This specific embodiment also provides an application of the Cordyceps militaris and Ganoderma lucidum spore powder composite preparation, comprising: dissolving the composite preparation in water to prepare a drinking granule.
[0054] It should be noted that the high carboxylic acid group density polyacrylic acid resin used in the following examples is Eudragit L; the low carboxylic acid group density polyacrylic acid resin is Eudragit S; the auxiliary agent is β -Cyclodextrins.
[0055] In some preferred embodiments, the composite preparation is not limited to being made into capsules (such as soft capsules or hard capsules), tablets, granules, granules, pills, powders, pastes, pill tablets, and capsules.
[0056] Example 1: A Cordyceps militaris and Ganoderma lucidum spore powder composite preparation and its application The present embodiment provides a composite preparation of Cordyceps militaris and Ganoderma lucidum spore powder, with a particle size of 60 μm, an outer layer of a polylactic acid-glycolic acid copolymer film, and an inner layer of composite particles of microcapsule-encapsulated Cordyceps militaris extract and microcapsule-encapsulated Ganoderma lucidum spore powder; The particle size of the composite particles is 4 μm, and the composite particles include the following components calculated by weight: 20 parts of microcapsule-coated Cordyceps militaris extract, 30 parts of microcapsule-coated Ganoderma lucidum spore powder, and 10 parts of adjuvant; The microcapsule encapsulates the Cordyceps militaris extract, and includes, from the outside to the inside: an enteric layer and the Cordyceps militaris extract; The microcapsule encapsulates the ganoderma spore powder, and comprises from the outside to the inside: a polymer sustained-release coating and the ganoderma spore powder.
[0057] The ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer is 1:5.
[0058] Then, the particle size of the microcapsule coated with Cordyceps militaris extract is 0.6 μm, and the thickness of the enteric layer is 20 nm; calculated by weight, the preparation method is as follows: S1, dissolving a high carboxylic acid group density polyacrylic acid resin and a low carboxylic acid group density polyacrylic acid resin in ethyl acetate, with a total weight of 10 parts, and stirring evenly to form a homogeneous polyacrylic acid resin solution; S2, adding 30 parts of Cordyceps militaris extract to the polyacrylic acid resin solution and stirring evenly; S3, adding 5 parts of emulsifier Tween 80 to form an emulsion; S4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; S5, adding 1.5 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming a wall material for the microcapsules; S6, continue to stir the emulsion to allow the cross-linking reaction to proceed fully until stable microcapsules are formed; S7, centrifuging and filtering to separate the microcapsules from the reaction mixture; S8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain the microcapsule-encapsulated Cordyceps militaris extract.
[0059] The particle size of the microcapsule-coated Ganoderma lucidum spore powder is 0.4 μm, and the thickness of the polymer sustained-release coating is 15 nm. The preparation method is as follows, calculated by weight: A1. Dissolve 10 parts of high carboxylic acid group density polyacrylic acid resin in ethyl acetate and stir evenly to form a homogeneous polyacrylic acid resin solution; A2, add 20 parts of Ganoderma lucidum spore powder into the polyacrylic acid resin solution and stir evenly; A3, add 5 parts of emulsifier Tween 80 to form an emulsion; A4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; A5, adding 0.75 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming the wall material of the microcapsule; A6. Continue stirring the emulsion to allow the crosslinking reaction to proceed fully until stable microcapsules are formed; A7, centrifuging and filtering to separate the microcapsules from the reaction mixture; A8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain microcapsule-encapsulated Ganoderma lucidum spore powder.
[0060] The mass ratio of the low carboxylic acid group density polyacrylic acid resin to the high carboxylic acid group density polyacrylic acid resin is calculated according to the following formula: ; in, is the mass ratio of the low carboxylic acid group density polyacrylic acid resin to the high carboxylic acid group density polyacrylic acid resin, and the unit is 1; It is the ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer, the unit is 1, and it is calculated based on the amount of cross-linking agent added, and the value is 0.53; is the thickness of the polymer sustained-release coating, in nm; is the thickness of the enteric layer in nm; In this embodiment, =0.4.
[0061] The preparation method of Cordyceps militaris extract adopts an alcohol extraction method; the wall breaking rate of Ganoderma lucidum spore powder is more than 90%.
[0062] The preparation method of the composite formulation provided in this embodiment is as follows: Step 1: Mix 20 parts of microcapsule-encapsulated Cordyceps militaris extract and 30 parts of microcapsule-encapsulated Ganoderma lucidum spore powder according to a certain proportion; Step 2: Add 10 parts of cyclodextrin and water and mix well; Step 3: granulate the uniformly mixed materials through a granulator to form composite particles; Step 4: dissolving PLGA in a solvent to form a PLGA solution; Step 5: Soaking the composite particles in a PLGA solution so that the surface of the composite particles is evenly coated with a layer of PLGA film; Step 6: Drying to form the composite preparation.
[0063] The present embodiment also provides an application of a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation, comprising: dissolving 30 g of the composite preparation in 100 g of water to prepare a drinking granule.
[0064] Example 2: A Cordyceps militaris and Ganoderma lucidum spore powder composite preparation and its application The present embodiment provides a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation, the particle size is 50 μm, the outer layer is a polylactic acid-glycolic acid copolymer film, and the inner layer is a composite particle of microcapsule-encapsulated Cordyceps militaris extract and microcapsule-encapsulated Ganoderma lucidum spore powder; The particle size of the composite particles is 3 μm, and the composite particles include the following components calculated by weight: 20 parts of microcapsule-encapsulated Cordyceps militaris extract, 35 parts of microcapsule-encapsulated Ganoderma lucidum spore powder, and 10 parts of adjuvant; The microcapsule encapsulates the Cordyceps militaris extract, and includes, from the outside to the inside: an enteric layer and the Cordyceps militaris extract; The microcapsule encapsulates the ganoderma spore powder, and comprises from the outside to the inside: a polymer sustained-release coating and the ganoderma spore powder.
[0065] The ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer is 1:5.
[0066] Then, the particle size of the microcapsule coated with Cordyceps militaris extract is 0.6 μm, and the thickness of the enteric layer is 20 nm; calculated by weight, the preparation method is as follows: S1, dissolving a high carboxylic acid group density polyacrylic acid resin and a low carboxylic acid group density polyacrylic acid resin in ethyl acetate, with a total weight of 10 parts, and stirring evenly to form a homogeneous polyacrylic acid resin solution; S2, adding 30 parts of Cordyceps militaris extract to the polyacrylic acid resin solution and stirring evenly; S3, adding 5 parts of emulsifier Tween 80 to form an emulsion; S4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; S5, adding 1.8 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming a wall material for the microcapsules; S6, continue to stir the emulsion to allow the cross-linking reaction to proceed fully until stable microcapsules are formed; S7, centrifuging and filtering to separate the microcapsules from the reaction mixture; S8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain the microcapsule-encapsulated Cordyceps militaris extract.
[0067] The particle size of the microcapsule-coated Ganoderma lucidum spore powder is 0.4 μm, and the thickness of the polymer sustained-release coating is 15 nm. The preparation method is as follows, calculated by weight: A1. Dissolve 10 parts of high carboxylic acid group density polyacrylic acid resin in ethyl acetate and stir evenly to form a homogeneous polyacrylic acid resin solution; A2, add 20 parts of Ganoderma lucidum spore powder into the polyacrylic acid resin solution and stir evenly; A3, add 5 parts of emulsifier Tween 80 to form an emulsion; A4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; A5, adding 0.8 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming the wall material of the microcapsule; A6. Continue stirring the emulsion to allow the crosslinking reaction to proceed fully until stable microcapsules are formed; A7, centrifuging and filtering to separate the microcapsules from the reaction mixture; A8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain microcapsule-encapsulated Ganoderma lucidum spore powder.
[0068] The mass ratio of the low carboxylic acid group density polyacrylic acid resin to the high carboxylic acid group density polyacrylic acid resin is calculated according to the following formula: ; in, is the mass ratio of the low carboxylic acid group density polyacrylic acid resin to the high carboxylic acid group density polyacrylic acid resin, and the unit is 1; It is the ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer, the unit is 1, and it is calculated based on the amount of cross-linking agent added, and the value is; is the thickness of the polymer sustained-release coating, in nm; is the thickness of the enteric layer in nm; In this embodiment, =0.33.
[0069] The preparation method of Cordyceps militaris extract adopts an alcohol extraction method; the wall breaking rate of Ganoderma lucidum spore powder is more than 90%.
[0070] The preparation method of the composite formulation provided in this embodiment is as follows: Step 1: Mix 20 parts of microcapsule-encapsulated Cordyceps militaris extract and 30 parts of microcapsule-encapsulated Ganoderma lucidum spore powder according to a certain proportion; Step 2: Add 10 parts of cyclodextrin and water and mix well; Step 3: granulate the uniformly mixed materials through a granulator to form composite particles; Step 4: dissolving PLGA in a solvent to form a PLGA solution; Step 5: Soaking the composite particles in a PLGA solution so that the surface of the composite particles is evenly coated with a layer of PLGA film; Step 6: Drying to form a composite preparation.
[0071] The present embodiment also provides an application of a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation, comprising: dissolving 30 g of the composite preparation in 100 g of water to prepare a drinking granule.
[0072] Example 3: A Cordyceps militaris and Ganoderma lucidum spore powder composite preparation and its application The present embodiment provides a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation, the particle size is 45 μm, the outer layer is a polylactic acid-glycolic acid copolymer film, and the inner layer is a composite particle of microcapsule-encapsulated Cordyceps militaris extract and microcapsule-encapsulated Ganoderma lucidum spore powder; The particle size of the composite particles is 6 μm, and the composite particles include the following components calculated by weight: 20 parts of microcapsule-coated Cordyceps militaris extract, 35 parts of microcapsule-coated Ganoderma lucidum spore powder, and 10 parts of adjuvant; The microcapsule encapsulates the Cordyceps militaris extract, and includes, from the outside to the inside: an enteric layer and the Cordyceps militaris extract; The microcapsule encapsulates the ganoderma spore powder, and comprises from the outside to the inside: a polymer sustained-release coating and the ganoderma spore powder.
[0073] The ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer is 1:5.
[0074] Then, the particle size of the microcapsule coated with Cordyceps militaris extract is 0.7 μm, and the thickness of the enteric layer is 20 nm; calculated by weight, the preparation method is as follows: S1, dissolving a high carboxylic acid group density polyacrylic acid resin and a low carboxylic acid group density polyacrylic acid resin in ethyl acetate, with a total weight of 10 parts, and stirring evenly to form a homogeneous polyacrylic acid resin solution; S2, adding 30 parts of Cordyceps militaris extract to the polyacrylic acid resin solution and stirring evenly; S3, adding 5 parts of emulsifier Tween 80 to form an emulsion; S4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; S5, adding 1.2 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming a wall material for the microcapsules; S6, continue to stir the emulsion to allow the cross-linking reaction to proceed fully until stable microcapsules are formed; S7, centrifuging and filtering to separate the microcapsules from the reaction mixture; S8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain the microcapsule-encapsulated Cordyceps militaris extract.
[0075] The particle size of the microcapsule-coated Ganoderma lucidum spore powder is 0.5 μm, and the thickness of the polymer sustained-release coating is 15 nm. The preparation method is as follows, calculated by weight: A1. Dissolve 10 parts of high carboxylic acid group density polyacrylic acid resin in ethyl acetate and stir evenly to form a homogeneous polyacrylic acid resin solution; A2, add 20 parts of Ganoderma lucidum spore powder into the polyacrylic acid resin solution and stir evenly; A3, add 5 parts of emulsifier Tween 80 to form an emulsion; A4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; A5, adding 0.8 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming the wall material of the microcapsule; A6. Continue stirring the emulsion to allow the crosslinking reaction to proceed fully until stable microcapsules are formed; A7, centrifuging and filtering to separate the microcapsules from the reaction mixture; A8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain microcapsule-encapsulated Ganoderma lucidum spore powder.
[0076] The mass ratio of the low carboxylic acid group density polyacrylic acid resin to the high carboxylic acid group density polyacrylic acid resin is calculated according to the following formula: ; in, is the mass ratio of the low carboxylic acid group density polyacrylic acid resin to the high carboxylic acid group density polyacrylic acid resin, and the unit is 1; It is the ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer, the unit is 1, and it is calculated based on the amount of cross-linking agent added, and the value is; is the thickness of the polymer sustained-release coating, in nm; is the thickness of the enteric layer in nm; In this embodiment, =0.5.
[0077] The preparation method of Cordyceps militaris extract adopts an alcohol extraction method; the wall breaking rate of Ganoderma lucidum spore powder is more than 90%.
[0078] The preparation method of the composite formulation provided in this embodiment is as follows: Step 1: Mix 20 parts of microcapsule-encapsulated Cordyceps militaris extract and 30 parts of microcapsule-encapsulated Ganoderma lucidum spore powder according to a certain proportion; Step 2: Add 10 parts of cyclodextrin and water and mix well; Step 3: granulate the uniformly mixed materials through a granulator to form composite particles; Step 4: dissolving PLGA in a solvent to form a PLGA solution; Step 5: Soaking the composite particles in a PLGA solution so that the surface of the composite particles is evenly coated with a layer of PLGA film; Step 6: Drying to form a composite preparation.
[0079] The present embodiment also provides an application of a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation, comprising: dissolving 30 g of the composite preparation in 100 g of water to prepare a drinking granule.
[0080] Comparative Example 1: A Cordyceps militaris and Ganoderma lucidum spore powder composite preparation and its application The present embodiment provides a composite preparation of Cordyceps militaris and Ganoderma lucidum spore powder, with a particle size of 60 μm, an outer layer of a polylactic acid-glycolic acid copolymer film, and an inner layer of composite particles of microcapsule-encapsulated Cordyceps militaris extract and microcapsule-encapsulated Ganoderma lucidum spore powder; The particle size of the composite particles is 4 μm, and the composite particles include the following components calculated by weight: 20 parts of microcapsule-coated Cordyceps militaris extract, 30 parts of microcapsule-coated Ganoderma lucidum spore powder, and 10 parts of adjuvant; The microcapsule encapsulates the Cordyceps militaris extract, and includes, from the outside to the inside: an enteric layer and the Cordyceps militaris extract; The microcapsule encapsulates the ganoderma spore powder, and comprises from the outside to the inside: a polymer sustained-release coating and the ganoderma spore powder.
[0081] The ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer is 1:5.
[0082] Then, the particle size of the microcapsule coated with Cordyceps militaris extract is 0.6 μm, and the thickness of the enteric layer is 20 nm; calculated by weight, the preparation method is as follows: S1, dissolving 10 parts of high carboxylic acid group density polyacrylic acid resin in ethyl acetate, stirring evenly to form a homogeneous polyacrylic acid resin solution; S2, adding 30 parts of Cordyceps militaris extract to the polyacrylic acid resin solution and stirring evenly; S3, adding 5 parts of emulsifier Tween 80 to form an emulsion; S4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; S5, adding 1.5 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming a wall material for the microcapsules; S6, continue to stir the emulsion to allow the cross-linking reaction to proceed fully until stable microcapsules are formed; S7, centrifuging and filtering to separate the microcapsules from the reaction mixture; S8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain the microcapsule-encapsulated Cordyceps militaris extract.
[0083] The particle size of the microcapsule-coated Ganoderma lucidum spore powder is 0.4 μm, and the thickness of the polymer sustained-release coating is 15 nm. The preparation method is as follows, calculated by weight: A1. Dissolve 10 parts of high carboxylic acid group density polyacrylic acid resin in ethyl acetate and stir evenly to form a homogeneous polyacrylic acid resin solution; A2, add 20 parts of Ganoderma lucidum spore powder into the polyacrylic acid resin solution and stir evenly; A3, add 5 parts of emulsifier Tween 80 to form an emulsion; A4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; A5, adding 0.75 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming the wall material of the microcapsule; A6. Continue stirring the emulsion to allow the crosslinking reaction to proceed fully until stable microcapsules are formed; A7, centrifuging and filtering to separate the microcapsules from the reaction mixture; A8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain microcapsule-encapsulated Ganoderma lucidum spore powder.
[0084] The preparation method of Cordyceps militaris extract adopts an alcohol extraction method; the wall breaking rate of Ganoderma lucidum spore powder is more than 90%.
[0085] The preparation method of the composite formulation provided in this embodiment is as follows: Step 1: Mix 20 parts of microcapsule-encapsulated Cordyceps militaris extract and 30 parts of microcapsule-encapsulated Ganoderma lucidum spore powder according to a certain proportion; Step 2: Add 10 parts of cyclodextrin and water and mix well; Step 3: granulate the uniformly mixed materials through a granulator to form composite particles; Step 4: dissolving PLGA in a solvent to form a PLGA solution; Step 5: Soaking the composite particles in a PLGA solution so that the surface of the composite particles is evenly coated with a layer of PLGA film; Step 6: Drying to form the composite preparation.
[0086] The present embodiment also provides an application of a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation, comprising: dissolving 30 g of the composite preparation in 100 g of water to prepare a drinking granule.
[0087] Comparative Example 2: A Cordyceps militaris and Ganoderma lucidum spore powder composite preparation and its application The present embodiment provides a composite preparation of Cordyceps militaris and Ganoderma lucidum spore powder, with a particle size of 60 μm, an outer layer of a polylactic acid-glycolic acid copolymer film, and an inner layer of composite particles of microcapsule-encapsulated Cordyceps militaris extract and microcapsule-encapsulated Ganoderma lucidum spore powder; The particle size of the composite particles is 4 μm, and the composite particles include the following components calculated by weight: 20 parts of microcapsule-coated Cordyceps militaris extract, 30 parts of microcapsule-coated Ganoderma lucidum spore powder, and 10 parts of adjuvant; The microcapsule encapsulates the Cordyceps militaris extract, and includes, from the outside to the inside: an enteric layer and the Cordyceps militaris extract; The microcapsule encapsulates the ganoderma spore powder, and comprises from the outside to the inside: a polymer sustained-release coating and the ganoderma spore powder.
[0088] The ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer is 1:5.
[0089] Then, the particle size of the microcapsule coated with Cordyceps militaris extract is 0.6 μm, and the thickness of the enteric layer is 20 nm; calculated by weight, the preparation method is as follows: S1. Dissolve 10 parts of low carboxylic acid group density polyacrylic acid resin in ethyl acetate and stir evenly to form a homogeneous polyacrylic acid resin solution; S2, adding 30 parts of Cordyceps militaris extract to the polyacrylic acid resin solution and stirring evenly; S3, adding 5 parts of emulsifier Tween 80 to form an emulsion; S4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; S5, adding 1.5 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming a wall material for the microcapsules; S6, continue to stir the emulsion to allow the cross-linking reaction to proceed fully until stable microcapsules are formed; S7, centrifuging and filtering to separate the microcapsules from the reaction mixture; S8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain the microcapsule-encapsulated Cordyceps militaris extract.
[0090] The particle size of the microcapsule-coated Ganoderma lucidum spore powder is 0.4 μm, and the thickness of the polymer sustained-release coating is 15 nm. The preparation method is as follows, calculated by weight: A1. Dissolve 10 parts of high carboxylic acid group density polyacrylic acid resin in ethyl acetate and stir evenly to form a homogeneous polyacrylic acid resin solution; A2, add 20 parts of Ganoderma lucidum spore powder into the polyacrylic acid resin solution and stir evenly; A3, add 5 parts of emulsifier Tween 80 to form an emulsion; A4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; A5, adding 0.75 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming the wall material of the microcapsule; A6. Continue stirring the emulsion to allow the crosslinking reaction to proceed fully until stable microcapsules are formed; A7, centrifuging and filtering to separate the microcapsules from the reaction mixture; A8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain microcapsule-encapsulated Ganoderma lucidum spore powder.
[0091] The preparation method of Cordyceps militaris extract adopts an alcohol extraction method; the wall breaking rate of Ganoderma lucidum spore powder is more than 90%.
[0092] The preparation method of the composite formulation provided in this embodiment is as follows: Step 1: Mix 20 parts of microcapsule-encapsulated Cordyceps militaris extract and 30 parts of microcapsule-encapsulated Ganoderma lucidum spore powder according to a certain proportion; Step 2: Add 10 parts of cyclodextrin and water and mix well; Step 3: granulate the uniformly mixed materials through a granulator to form composite particles; Step 4: dissolving PLGA in a solvent to form a PLGA solution; Step 5: Soaking the composite particles in a PLGA solution so that the surface of the composite particles is evenly coated with a layer of PLGA film; Step 6: Drying to form the composite preparation.
[0093] The present embodiment also provides an application of a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation, comprising: dissolving 30 g of the composite preparation in 100 g of water to prepare a drinking granule.
[0094] Comparative Example 3: A Cordyceps militaris and Ganoderma lucidum spore powder composite preparation and its application
[0095] The present embodiment provides a composite preparation of Cordyceps militaris and Ganoderma lucidum spore powder, with a particle size of 60 μm, an outer layer of a polylactic acid-glycolic acid copolymer film, and an inner layer of composite particles of microcapsule-encapsulated Cordyceps militaris extract and microcapsule-encapsulated Ganoderma lucidum spore powder; The particle size of the composite particles is 4 μm, and the composite particles include the following components calculated by weight: 20 parts of microcapsule-coated Cordyceps militaris extract, 30 parts of microcapsule-coated Ganoderma lucidum spore powder, and 10 parts of adjuvant; The microcapsule encapsulates the Cordyceps militaris extract, and includes, from the outside to the inside: an enteric layer and the Cordyceps militaris extract; The microcapsule encapsulates the ganoderma spore powder, and comprises from the outside to the inside: a polymer sustained-release coating and the ganoderma spore powder.
[0096] The ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer is 1:5.
[0097] Then, the particle size of the microcapsule coated with Cordyceps militaris extract is 0.6 μm, and the thickness of the enteric layer is 20 nm; calculated by weight, the preparation method is as follows: S1, dissolving 5 parts of high carboxylic acid group density polyacrylic acid resin and 5 parts of low carboxylic acid group density polyacrylic acid resin in ethyl acetate, with a total weight of 10 parts, and stirring evenly to form a homogeneous polyacrylic acid resin solution; S2, adding 30 parts of Cordyceps militaris extract to the polyacrylic acid resin solution and stirring evenly; S3, adding 5 parts of emulsifier Tween 80 to form an emulsion; S4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; S5, adding 1.5 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming a wall material for the microcapsules; S6, continue to stir the emulsion to allow the cross-linking reaction to proceed fully until stable microcapsules are formed; S7, centrifuging and filtering to separate the microcapsules from the reaction mixture; S8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain the microcapsule-encapsulated Cordyceps militaris extract.
[0098] The particle size of the microcapsule-coated Ganoderma lucidum spore powder is 0.4 μm, and the thickness of the polymer sustained-release coating is 15 nm. The preparation method is as follows, calculated by weight: A1. Dissolve 10 parts of high carboxylic acid group density polyacrylic acid resin in ethyl acetate and stir evenly to form a homogeneous polyacrylic acid resin solution; A2, add 20 parts of Ganoderma lucidum spore powder into the polyacrylic acid resin solution and stir evenly; A3, add 5 parts of emulsifier Tween 80 to form an emulsion; A4, emulsifying the emulsion under high-speed stirring to form stable emulsion particles; A5, adding 0.75 parts of glutaraldehyde crosslinking agent dropwise into the emulsion to form crosslinks between polyacrylic acid resin molecules, thereby forming the wall material of the microcapsule; A6. Continue stirring the emulsion to allow the crosslinking reaction to proceed fully until stable microcapsules are formed; A7, centrifuging and filtering to separate the microcapsules from the reaction mixture; A8, washing the microcapsules to remove unreacted polyacrylic acid resin and other impurities, and drying to obtain microcapsule-encapsulated Ganoderma lucidum spore powder.
[0099] The preparation method of Cordyceps militaris extract adopts an alcohol extraction method; the wall breaking rate of Ganoderma lucidum spore powder is more than 90%.
[0100] The preparation method of the composite formulation provided in this embodiment is as follows: Step 1: Mix 20 parts of microcapsule-encapsulated Cordyceps militaris extract and 30 parts of microcapsule-encapsulated Ganoderma lucidum spore powder according to a certain proportion; Step 2: Add 10 parts of cyclodextrin and water and mix well; Step 3: granulate the uniformly mixed materials through a granulator to form composite particles; Step 4: dissolving PLGA in a solvent to form a PLGA solution; Step 5: Soaking the composite particles in a PLGA solution so that the surface of the composite particles is evenly coated with a layer of PLGA film; Step 6: Drying to form the composite preparation.
[0101] The present embodiment also provides an application of a Cordyceps militaris and Ganoderma lucidum spore powder composite preparation, comprising: dissolving 30 g of the composite preparation in 100 g of water to prepare a drinking granule.
[0102] The composite granules obtained in Examples 1 to 3 and Comparative Examples 1 to 3 were subjected to an in vitro enteric test, and the specific method is as follows: 1. Experimental Equipment and Materials Dissolution apparatus: Use USP dissolution tester.
[0103] Dissolution media: simulated gastric fluid (pH=1.2), simulated intestinal fluid (pH=6.8) and simulated colon fluid (pH=7.4).
[0104] Preparation samples: composite preparations of Examples 1 to 3 and Comparative Examples 1 to 3.
[0105] 2. Experimental Procedure (1) Simulation of gastric environment: To evaluate the ability of the drug to remain stable in the acidic environment of the stomach, the composite preparations obtained in Examples 1 to 3 and Comparative Examples 1 to 3 were placed in simulated gastric fluid at pH = 1.2 for 1 hour. Samples were taken regularly during this period to measure the amount of drug released.
[0106] (2) Transfer to the intestinal environment to simulate the dissolution and release of the drug in the intestine. The preparation is removed from the gastric fluid and transferred to simulated intestinal fluid with a pH of 6.8. This process is carried out at 37°C to simulate human body temperature. The dissolution is continued for 2 hours, and samples are taken regularly to measure the amount of drug released.
[0107] Table 1. Preparation parameters and test results
[0108] According to the comparison between Comparative Example 1 and Example 1, it can be seen that when high carboxylic acid group density polyacrylate is completely used as the wall material, the Cordyceps militaris extract is partially released in the gastric juice, which shows that the Cordyceps militaris extract has been eroded by the gastric juice in the gastric juice, and the Cordyceps militaris extract is released in the intestinal juice at a faster rate, almost the same as the rate of Ganoderma lucidum spore powder, but the absorption time of Ganoderma lucidum spore powder is longer than that of the Cordyceps militaris extract, which will result in that when the Cordyceps militaris has been completely absorbed, part of the Ganoderma lucidum spore powder has not been absorbed, affecting the synergistic effect of the two components.
[0109] According to the comparison between Comparative Example 2 and Example 1, it can be seen that when low carboxylic acid group density polyacrylate is completely used as the wall material, the Cordyceps militaris extract does not dissolve in the gastric juice, but the release rate in the intestinal juice is also slow, while the release rate of the Ganoderma lucidum spore powder is faster. Although the absorption of the Ganoderma lucidum spore powder takes a longer time, since the Ganoderma lucidum spore powder has been processed by the gastric juice in the gastric juice, its absorption rate by the small intestine will be faster than that of the slowly released Cordyceps militaris extract, which also affects the synergistic effect of the two components.
[0110] According to the comparison between Comparative Example 3 and Example 1, when the wall material of the microcapsule encapsulating the Cordyceps militaris extract adopts a mass ratio of low carboxylic acid group density polyacrylic resin to high carboxylic acid group density polyacrylic resin of 1:1, due to the excessive proportion of low carboxylic acid group density polyacrylic resin, the dissolution rate of the wall material in the intestinal fluid is reduced, which also affects the absorption of the Cordyceps militaris extract.
[0111] The above description is only a preferred embodiment of the present invention and does not constitute any form of limitation to the present invention. Although the present invention has been presented as a preferred embodiment as above, it is not intended to limit the present invention. Any technician familiar with the profession can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention still falls within the scope of the technical solution of the present invention.
Claims
1. A Cordyceps militaris and Ganoderma lucidum spore powder composite preparation, characterized in that: The composite preparation is microcapsule-embedded particles, the outer layer of which is a polylactic acid-glycolic acid copolymer film, and the inner layer is composite particles of microcapsule-coated Cordyceps militaris extract and microcapsule-coated Ganoderma lucidum spore powder; Calculated by weight, the composite particles include the following components: 20 parts of microcapsule-encapsulated Cordyceps militaris extract, 30 or 35 parts of microcapsule-encapsulated Ganoderma lucidum spore powder and 10 parts of adjuvant; The microcapsule encapsulates the Cordyceps militaris extract, and includes, from the outside to the inside: an enteric layer and the Cordyceps militaris extract; The microcapsule encapsulates the ganoderma spore powder, and comprises from the outside to the inside: a polymer sustained-release coating and the ganoderma spore powder.
2. The Cordyceps militaris and Ganoderma lucidum spore powder composite preparation according to claim 1, characterized in that: The materials of the polymer sustained-release coating and the enteric layer are both polyacrylic acid resin; The ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer is 1:
5.
3. A Cordyceps militaris and Ganoderma lucidum spore powder composite preparation according to claim 2, characterized in that: The material of the enteric layer includes a high carboxylic acid group density polyacrylic acid resin and a low carboxylic acid group density polyacrylic acid resin.
4. The Cordyceps militaris and Ganoderma lucidum spore powder composite preparation according to claim 3, characterized in that: The mass ratio of the low carboxylic acid group density polyacrylic resin to the high carboxylic acid group density polyacrylic resin is calculated according to the following formula: ; in, is the mass ratio of the low carboxylic acid group density polyacrylic acid resin to the high carboxylic acid group density polyacrylic acid resin, and the unit is 1; It is the ratio of the cross-linking density of the polymer sustained-release coating to the cross-linking density of the enteric layer, and the unit is 1; is the thickness of the polymer sustained-release coating, in nm; is the thickness of the enteric layer, in nm.
5. The Cordyceps militaris and Ganoderma lucidum spore powder composite preparation according to claim 1, characterized in that: The particle size of the composite preparation is 45, 50 or 60 μm.
6. The Cordyceps militaris and Ganoderma lucidum spore powder composite preparation according to claim 1, characterized in that: The particle size of the composite particles is 3, 4 or 6 μm.
7. The Cordyceps militaris and Ganoderma lucidum spore powder composite preparation according to claim 1, characterized in that: The particle size of the microcapsule-coated Cordyceps militaris extract is 0.6 or 0.7 μm; the particle size of the microcapsule-coated Ganoderma lucidum spore powder is 0.4 or 0.5 μm.
8. The Cordyceps militaris and Ganoderma lucidum spore powder composite preparation according to claim 7, characterized in that: The preparation method of the microcapsule-coated Cordyceps militaris extract is as follows: Dissolving polyacrylic acid resin in a solvent and stirring evenly to form a homogeneous polyacrylic acid resin solution; Add the Cordyceps militaris extract to the polyacrylic acid resin solution and stir evenly; Add an appropriate amount of emulsifier to form an emulsion; The emulsion is emulsified under high-speed stirring to form stable emulsion particles; Adding a cross-linking agent dropwise into the emulsion to form cross-links between polyacrylic acid resin molecules, thereby forming the wall material of the microcapsule; Continue stirring the emulsion to allow the cross-linking reaction to proceed fully until stable microcapsules are formed; Centrifugation and filtration to separate the microcapsules from the reaction mixture; The microcapsules are washed to remove unreacted polyacrylic acid resin and other impurities, and then dried to obtain the microcapsule-coated Cordyceps militaris extract.
9. The Cordyceps militaris and Ganoderma lucidum spore powder composite preparation according to claim 7, characterized in that: The preparation method of the composite preparation is as follows: Mixing the microcapsule-encapsulated Cordyceps militaris extract and the microcapsule-encapsulated Ganoderma lucidum spore powder in proportion; Add auxiliary agents and mix well; The uniformly mixed materials are granulated by a granulator to form composite particles; dissolving PLGA in a solvent to form a PLGA solution; The composite particles are immersed in a PLGA solution so that the surface of the composite particles is evenly coated with a layer of PLGA film; and drying to form the composite preparation.
Citation Information
Patent Citations
Composite capable of enhancing human body immunity
CN102973615A
Garlic and glossy ganoderma formula and preparation for enhancing immunity, and preparation method
CN108125227A
Particle size variable anti-tumor bionic nano preparation based on PLGA and preparation method and application thereof
CN113456614A
Ternary composite microsphere formulation and its preparation method
CN1557283A
Microparticles and nanoparticles having negative surface charges
US20210169819A1
